Startup 10x Science Raises $4.8M to Use AI for Characterizing Drug Candidates
Founded in December 2025, 10x Science has secured a $4.8 million seed funding round, spearheaded by Initialized Capital and supported by Y Combinator, Civilization Ventures, and Founder Factor. The startup's mission is to tackle challenges in drug development by analyzing AI-generated drug candidates. The team, which includes founders David Roberts, Andrew Reiter, and Vishnu Tejas—who previously worked in Dr. Carolyn Bertozzi’s lab at Stanford—is creating a platform that integrates deterministic algorithms with AI to analyze mass spectrometry data. Matthew Crawford, a scientist at Rilas Technologies, notes that this platform enhances analysis speed. 10x is partnering with leading pharmaceutical firms and intends to utilize the funding for hiring and refining its models, aiming for regulatory compliance as a SaaS solution for the industry.
Key facts
- 10x Science raised a $4.8 million seed round led by Initialized Capital.
- The startup was founded in December 2025.
- Founders are David Roberts, Andrew Reiter, and Vishnu Tejas.
- The team previously worked in Nobel laureate Dr. Carolyn Bertozzi’s Stanford lab.
- The platform uses AI to interpret mass spectrometry data for drug candidate characterization.
- Scientist Matthew Crawford of Rilas Technologies has tested the platform and found it speeds up analysis.
- 10x is working with multiple major pharmaceutical companies and academic researchers.
- The funding will be used to hire engineers and refine the model.
Entities
Institutions
- 10x Science
- Google DeepMind
- Initialized Capital
- Y Combinator
- Civilization Ventures
- Founder Factor
- TechCrunch
- Merck
- Stanford
- Rilas Technologies